Home » Topics » BioWorld Science

BioWorld Science
RSS

Myonexus Therapeutics initiates study of first-ever gene therapy for beta-sarcoglycanopathy

Nov. 9, 2018

Codexis announces topline results from phase Ia study of CDX-6114

Nov. 9, 2018

Oncobiologics begins first clinical trial for ONS-5010 in wet AMD

Nov. 9, 2018

Study points to new bone building strategy

Nov. 9, 2018

AstraZeneca initiates first-in-human study of AZD-9833 in advanced breast cancer

Nov. 8, 2018

Visterra initiates first-in-human study with VIS-649 for IgA nephropathy

Nov. 8, 2018

Enrollment open in phase II study of Blautix for IBS

Nov. 8, 2018

Immunomedics and AstraZeneca to study sacituzumab and durvalumab in metastatic NSCLC

Nov. 8, 2018

PledPharma initiates phase III program with PledOx

Nov. 8, 2018

Voyager Therapeutics reports longer-term data from phase Ib study of VY-AADC in Parkinson's disease

Nov. 8, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...